Cimpress vs New York Times
CMPR and NYT side by side, both in printing, publishing, and allied industries. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CMPR and NYT compare
New York Times is the larger company, worth 8.2 times as much as Cimpress ($11.3B against $1.4B).
On earnings, Cimpress is cheaper: it trades at 17.0× trailing earnings, against 29.4× for New York Times.
New York Times grew revenue faster over the last twelve months (10.8% versus 10.0% for Cimpress).
New York Times keeps more of each dollar of sales as profit, with a net margin of 13.2% compared with 2.2% at Cimpress.
New York Times pays a dividend yielding 1.2%; Cimpress does not pay one.
New York Times scores higher on the StockData Score (20 against 10 for Cimpress), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CMPR | NYT |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $11.3B |
| Share price | $57.02 | $70.17 |
| Change, 1 year | −14.6% | 25.1% |
| Change, 5 years | −38.3% | 39.9% |
| Beta (5Y) | 1.39 | 0.54 |
| Employees | 500 | 6,000 |
| StockData Score | ||
| Total score | 10 | 20 (better) |
| Valuation score | 6 (better) | 2 |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 17.0× (better) | 29.4× |
| P/S | 0.4× (better) | 3.8× |
| P/B | – | 5.5× |
| EV/EBITDA | 7.6× (better) | 19.1× |
| P/FCF | 7.3× (better) | 18.2× |
| PEG | – | 1.12 |
| FCF yield | 13.7% (better) | 5.5% |
| Fair value | $82.98 | $54.44 |
| Margin of safety | 31.3% (better) | −28.9% |
| Growth | ||
| Revenue growth (TTM) | 10.0% | 10.8% (better) |
| Revenue growth, 5Y average | 7.7% | 9.6% (better) |
| Net income growth (TTM) | 144% (better) | 22.6% |
| EPS growth (TTM) | 155% (better) | 23.2% |
| EPS growth, 5Y average | – | 28.4% |
| Profitability | ||
| Gross margin | 45.6% | 51.4% (better) |
| Operating margin | 6.0% | 16.0% (better) |
| Net margin | 2.2% | 13.2% (better) |
| FCF margin | 5.0% | 20.9% (better) |
| Return on equity | – | 19.7% |
| Return on invested capital | 16.6% | 26.9% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 3.93 | – |
| Current ratio | 0.63 | 1.58 (better) |
| Altman Z-score | 2.36 | 10.17 (better) |
| Piotroski F-score | 8 | 9 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.2% |
| Payout ratio | – | 32.1% |
| Years of dividend growth | – | 7 |
| Dividend growth, 5Y average | – | 24.6% |
| Buyback yield | 3.4% (better) | 1.5% |
| Shareholder yield | 3.4% (better) | 2.8% |
| Ownership | ||
| Held by institutions | 87.7% | 103% |
| Held by insiders | 28.8% | 1.5% |
| Insider net buying, 12 months | −$9.0M (better) | −$9.8M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 13.2% | 11.6% |
Go deeper
- CMPR stock overview
- CMPR income statement
- CMPR valuation and score
- NYT stock overview
- NYT income statement
- NYT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.